乳腺癌肝转移患者TARE后免疫激活与PET/CT反应的前瞻性评估
本前瞻性初步研究纳入23例计划接受TARE的乳腺癌肝转移女性,分析外周血和肝肿瘤活检免疫标志物与PET/CT完全缓解的关系。20例可评估者中40%达到CR,CR者基线外周单核细胞和MDSC更低、PD-1阳性CD4+ TIL更高,TARE后外周IL-6、IL-10、IL-15及组织LAG-3阳性CD4+ TIL升高。
要点
- 基线低单核细胞和MDSC、高PD-1+ CD4+ TIL与TARE后PET/CT完全缓解相关。
- TARE后外周IL-6、IL-10、IL-15及肿瘤LAG-3+ CD4+ TIL升高提示免疫激活。
- PET/CT采用mRECIST评估CR,CR率40%(95% CI 19–64)。
关键影像表现/征象
- TARE后外周IL-6几何均值从1.0升至1.6 pg/mL(P=.02)。
- TARE后外周IL-10几何均值从0.2升至0.4 pg/mL(P=.001)。
- TARE后外周IL-15几何均值从1.9升至2.4 pg/mL(P=.01)。
- TARE后活检组织LAG-3阳性CD4+ TIL从15%升至31%(P<.001)。
- CR者基线流式显示外周单核细胞10% vs 29%(P<.001)、MDSC 1% vs 5%(P<.001)、PD-1阳性CD4+ TIL 59% vs 26%(P=.006),肿瘤PD-1+染色2% vs 1%(P=.046)。
诊断标准与关键数值
- 采用mRECIST在PET/CT上判定治疗组织完全缓解(CR),20例中8例(40%,精确95% CI:19–64)达到CR。
- CR组基线外周单核细胞10% vs 非CR组29%(P<.001),MDSC 1% vs 5%(P<.001)。
- CR组基线PD-1阳性CD4+ TIL 59% vs 非CR组26%(P=.006),肿瘤PD-1+染色2% vs 1%(P=.046)。
临床应用与阅片要点
- TARE后1-2个月PET/CT评估CR时,可结合基线外周单核细胞、MDSC和PD-1+ TIL水平预判反应。
- 关注TARE后外周IL-6、IL-10、IL-15及组织LAG-3+ CD4+ TIL升高,提示免疫激活。
- mRECIST用于PET/CT评估治疗组织CR,报告时应明确所用标准。
局限性
- 前瞻性初步研究,样本量小(最终20例分析),单中心。
- TARE后活检和血液采集时间为1-2个月,未报告长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The impact of transarterial radioembolization (TARE) of breast cancer liver metastasis (BCLM) on antitumor immunity is unknown, which hinders the optimal selection of candidates for TARE. Purpose To determine whether response to TARE at PET/CT in participants with BCLM is associated with specific immune markers (cytokines and immune cell populations). Materials and Methods This prospective pilot study enrolled 23 women with BCLM who planned to undergo TARE (June 2018 to February 2020). Peripheral blood and liver tumor biopsies were collected at baseline and 1-2 months after TARE. Monocyte, myeloid-derived suppressor cell (MDSC), interleukin (IL), and tumor-infiltrating lymphocyte (TIL) levels were assessed with use of gene expression studies and flow cytometry, and immune checkpoint and cell surface marker levels with immunohistochemistry. Modified PET Response Criteria in Solid Tumors was used to determine complete response (CR) in treated tissue. After log-transformation, immune marker levels before and after TARE were compared using paired t tests. Association with CR was assessed with Wilcoxon rank-sum or unpaired t tests. Results Twenty women were included. After TARE, peripheral IL-6 (geometric mean, 1.0 vs 1.6 pg/mL; P = .02), IL-10 (0.2 vs 0.4 pg/mL; P = .001), and IL-15 (1.9 vs 2.4 pg/mL; P = .01) increased. In biopsy tissue, lymphocyte activation gene 3-positive CD4+ TILs (15% vs 31%; P < .001) increased. Eight of 20 participants (40% [exact 95% CI: 19, 64]) achieved CR. Participants with CR had lower baseline peripheral monocytes (10% vs 29%; P < .001) and MDSCs (1% vs 5%; P < .001) and higher programmed cell death protein (PD) 1-positive CD4+ TILs (59% vs 26%; P = .006) at flow cytometry and higher PD-1+ staining in tumor (2% vs 1%; P = .046). Conclusion Complete response to transarterial radioembolization was associated with lower baseline cytokine, monocyte, and myeloid-derived suppressor cell levels and higher programmed cell death protein 1-positive tumor-infiltrating lymphocyte levels. © RSNA, 2022 Online supplemental material is available for this article.
引用
- Deipolyi, Johnson, Riedl, et al. Prospective Evaluation of Immune Activation Associated with Response to Radioembolization Assessed with PET/CT in Women with Breast Cancer Liver Metastasis. Radiology. 2022. PMID: 35972356. doi:10.1148/radiol.220158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。